Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

K. Tryfonidis · SciRah

Researcher profile · Semantic Scholar

K. Tryfonidis

Share profile

K. Tryfonidis — researcher profile on SciRah

h-index: 24
Works: 82
Citations: 5,134

Most-cited papers

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
F. Cardoso, L. V. van'T Veer, J. Bogaerts, L. Slaets +30 more
2016New England Journal of Medicine1,633 citations Open access
Semantic Scholar
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
P. Schmid, J. Cortés, R. Dent, L. Pusztai +26 more
2022New England Journal of Medicine956 citations Open access
Semantic Scholar
Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study.
L. E. Elshof, K. Tryfonidis, L. Slaets, A. E. van Leeuwen-Stok +6 more
2015European Journal of Cancer366 citations Open access
Semantic Scholar
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
F. Cardoso, J. Bartlett, L. Slaets, C. V. van Deurzen +32 more
2017Annals of Oncology357 citations Open access
Semantic Scholar
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
M. Piccart, L. J. van 't Veer, C. Poncet, J. L. Lopes Cardozo +28 more
2021The Lancet Oncology298 citations Open access
Semantic Scholar
Management of locally advanced breast cancer—perspectives and future directions
K. Tryfonidis, E. Senkus, M. Cardoso, F. Cardoso
2015Nature Reviews Clinical Oncology150 citations Open access
Semantic Scholar
Endocrine treatment in breast cancer: Cure, resistance and beyond.
K. Tryfonidis, D. Zardavas, B. Katzenellenbogen, M. Piccart
2016Cancer Treatment Reviews141 citations
Semantic Scholar
VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC
P. Schmid, J. Cortes, R. Dent, L. Pusztai +16 more
2021134 citations Open access
Semantic Scholar
Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives.
K. Aalders, K. Tryfonidis, E. Senkus, F. Cardoso
2017Cancer Treatment Reviews107 citations
Semantic Scholar
Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
H. Wildiers, K. Tryfonidis, L. dal Lago, P. Vuylsteke +7 more
2018The Lancet Oncology103 citations
Semantic Scholar
Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
M. Vermeulen, L. Slaets, F. Cardoso, S. Giordano +11 more
2017European Journal of Cancer93 citations Open access
Semantic Scholar
Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials.
I. Ghislain, E. Zikos, C. Coens, C. Quinten +10 more
2016The Lancet Oncology86 citations Open access
Semantic Scholar
Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial
G. Viale, F. de Snoo, L. Slaets, J. Bogaerts +11 more
2017Breast Cancer Research and Treatment67 citations
Semantic Scholar
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial
M. Ignatiadis, S. Litière, F. Rothé, S. Riethdorf +16 more
2018Annals of Oncology65 citations Open access
Semantic Scholar
The past and future of breast cancer treatment—from the papyrus to individualised treatment approaches
F. Ades, K. Tryfonidis, D. Zardavas
2017ecancermedicalscience52 citations Open access
Semantic Scholar
Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial.
M. Ignatiadis, B. Rack, F. Rothé, S. Riethdorf +15 more
2016European Journal of Cancer49 citations
Semantic Scholar
Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study
N. Turner, J. Balmaña, C. Poncet, T. Goulioti +25 more
2021Clinical Cancer Research41 citations Open access
Semantic Scholar
Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.
L. Pusztai, C. Denkert, J. O'Shaughnessy, J. Cortés +15 more
2022Journal of Clinical Oncology40 citations
Semantic Scholar
Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
S. C. Doebar, L. Slaets, F. Cardoso, S. Giordano +12 more
2017Modern Pathology38 citations Open access
Semantic Scholar
A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378).
K. Tryfonidis, G. Basaran, J. Bogaerts, M. Debled +7 more
2016European Journal of Cancer36 citations
Semantic Scholar
The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics.
J. Menis, S. Litière, K. Tryfonidis, V. Golfinopoulos
2016Annals of Translational Medicine35 citations Open access
Semantic Scholar
Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
F. Cardoso, L. V. van'T Veer, J. Bogaerts, L. Slaets +30 more
201635 citations
Semantic Scholar
CDK4/6 blockade in breast cancer: current experience and future perspectives
D. Zardavas, N. Pondé, K. Tryfonidis
2017Expert Opinion on Investigational Drugs31 citations
Semantic Scholar
Abstract S6-05: Characterization of male breast cancer: First results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program
F. Cardoso, J. Bartlett, L. Slaets, C. V. van Deurzen +32 more
201525 citations
Semantic Scholar
Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.
K. Aalders, A. Kuijer, M. Straver, L. Slaets +10 more
2017European Journal of Cancer18 citations
Semantic Scholar
An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint®).
M. Makama, C. Drukker, E. J. Th. Rutgers, L. Slaets +5 more
2017European Journal of Cancer16 citations
Semantic Scholar
Targeted adjuvant therapy in breast cancer
D. Zardavas, K. Tryfonidis, T. Goulioti, M. Piccart
2016Expert Review of Anticancer Therapy15 citations
Semantic Scholar
Small breast cancers: when and how to treat.
K. Tryfonidis, D. Zardavas, F. Cardoso
2014Cancer Treatment Reviews14 citations
Semantic Scholar
A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer.
K. Tryfonidis, I. Boukovinas, N. Xenidis, C. Christophyllakis +7 more
2013Breast12 citations Open access
Semantic Scholar
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
F. Cardoso, K. Hirshfield, Kimberly A Kraynyak, K. Tryfonidis +1 more
2024npj Breast Cancer11 citations
Semantic Scholar
Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.
S. Delaloge, M. Piccart, E. Rutgers, S. Litière +25 more
2020Journal of Clinical Oncology11 citations Open access
Semantic Scholar
Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial.
L. dal Lago, A. Uwimana, C. Coens, P. Vuylsteke +10 more
2022Journal of Geriatric Oncology10 citations Open access
Semantic Scholar
Abstract OT1-03-05: A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician's choice in previously- treated, HER2 negative, germline BRCA mutation-positive breast cancer patients. An EORTC-BIG intergroup study (BRAVO study)
J. Balmaña, K. Tryfonidis, W. Audeh, Theodora Goulioti +5 more
201610 citations
Semantic Scholar
Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses
P. Schmid, J. Cortés, R. Dent, L. Pusztai +26 more
2022Cancer Research9 citations
Semantic Scholar
Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer.
Nathan Touati, K. Tryfonidis, F. Caramia, H. Bonnefoi +4 more
2016European Journal of Cancer9 citations Open access
Semantic Scholar
A phase III randomized trial of niraparib versus physician’s choice in previously treated, HER2-negative, germline-BRCA mutated breast cancer patients: Intergroup study EORTC-1307-BCG and BIG5-13.
K. Tryfonidis, J. Bogaerts, R. Martell, G. Sledge +12 more
20149 citations
Semantic Scholar
HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer.
E. Hamilton, Miguel Martín, C. O'Sullivan, G. Curigliano +6 more
2023Journal of Clinical Oncology8 citations
Semantic Scholar
Detection of circulating cytokeratin-19 mRNA-positive cells in the blood and the mitotic index of the primary tumor have independent prognostic value in early breast cancer.
K. Tryfonidis, M. Kafousi, M. Perraki, S. Apostolaki +4 more
2014Clinical Breast Cancer7 citations
Semantic Scholar
150O_PRNot all small node negative (pT1abN0) breast cancers are similar: Outcome results from an EORTC 10041/BIG 3-04 (MINDACT) trial substudy
K. Tryfonidis, C. Poncet, L. Slaets, G. Viale +7 more
20176 citations Open access
Semantic Scholar
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers
F. Hilbers, C. Poncet, K. Tryfonidis, G. Viale +9 more
2024npj Breast Cancer4 citations Open access
Semantic Scholar
Abstract OT3-07-01: Update of the randomized, non-inferiority LORD trial testing safety of active surveillance for women with screen-detected low risk ductal carcinoma in situ (EORTC-1401-BCG/BOOG 2014-04, DCIS)
J. Wesseling, L. E. Elshof, K. Tryfonidis, C. Poncet +11 more
20184 citations
Semantic Scholar
Abstract CT065: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)
E. Hamilton, J. Tsurutani, J. Sohn, G. Curigliano +6 more
2023Cancer Research3 citations
Semantic Scholar
Very low risk of locoregional breast cancer recurrence in the EORTC 10041/BIG 03-04 MINDACT trial: Analysis of risk factors including the 70-gene signature
E. Rutgers, K. Aalders, C. Poncet, F. Cardoso +7 more
20183 citations
Semantic Scholar
Standard anthracycline-based vs. docetaxel-capecitabine in early breast cancer: Results from the chemotherapy randomization (R-C) of EORTC 10041/ BIG 3-04 MINDACT phase III trial.
F. Cardoso, M. Piccart-Gebhart, E. Rutgers, S. Litière +16 more
20173 citations
Semantic Scholar
SEER-Medicare study of early-stage triple-negative breast cancer: Real-world treatment patterns, survival, and expenditures 2010 to 2016.
J. Sieluk, A. Haiderali, Min Huang, Ling-Feng Yang +2 more
20202 citations
Semantic Scholar
Abstract OT3-04-03: KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2–breast cancer
F. Cardoso, A. Bardia, F. André, D. Cescon +11 more
2019Ongoing Clinical Trials2 citations
Semantic Scholar
Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trial
K. Aalders, Nathan Touati, K. Tryfonidis, M. Annonay +6 more
2018Breast Cancer Research and Treatment2 citations Open access
Semantic Scholar
Abstract P1-07-08: Young age and the risk of disease recurrence as assessed by the 70-gene signature – an analysis from the EORTC 10041/BIG 03-04 MINDACT trial
K. Aalders, E. Genbrugge, C. Poncet, A. Kuijer +7 more
20182 citations
Semantic Scholar
Abstract P4-12-01: MammaPrint is cost-effective compared to clinical risk assessment in early stage breast cancer
V. Retèl, M. Joore, L. J. van 't Veer, F. Cardoso +5 more
20182 citations
Semantic Scholar
Abstract P5-23-01: Clinical and biological characterization of male breast cancer (BC) EORTC 10085/TBCRC 029/BOOG 2013-02/BIG 2-07: Baseline results from the prospective registry
S. Giordano, C. Schröder, C. Poncet, E. van Leeuwen-Stok +27 more
20182 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

F. Cardoso×24
Invite
F. Cardoso — researcher profile on SciRah
L. Slaets×13
Invite
L. Slaets — researcher profile on SciRah
M. Piccart×12
Invite
M. Piccart — researcher profile on SciRah
C. Poncet×12
Invite
C. Poncet — researcher profile on SciRah

×11

Invite

J. Bogaerts — researcher profile on SciRah

T. Goulioti×10

Invite

T. Goulioti — researcher profile on SciRah

Invite

K. Aalders — researcher profile on SciRah

Invite

I. Rubio — researcher profile on SciRah

P. Vuylsteke×9

Invite

P. Vuylsteke — researcher profile on SciRah

Invite

S. Litière — researcher profile on SciRah

Invite

E. Brain — researcher profile on SciRah

L. J. van 't Veer×8

Invite

L. J. van 't Veer — researcher profile on SciRah